TY - JOUR
T1 - Cancer chemoprevention
T2 - Much has been done, but there is still much to do. State of the art and possible new approaches
AU - Serrano, Davide
AU - Lazzeroni, Matteo
AU - Bonanni, Bernardo
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Over the past three decades great efforts have been made in search of cancer chemoprevention strategies. The increase in knowledge of the long process from normal to cancer cell has enabled interventions in terms of lifestyle modifications, natural compounds or drugs to block or reverse the process. Great successes have been achieved, especially for breast and colorectal cancer. However, these strategies have yet to find clinical application on a large scale.In this article we identify the achievements, the pitfalls and the next steps to be taken to improve the efficacy and applicability of chemoprevention strategies. Among the crucial key points to be implemented are educational activities for physicians to appropriately disseminate the aim and indeed the culture of chemoprevention. It is essential to improve the risk-benefit balance, seeking the minimal active doses, intermittent schedules, a better characterization of the risk categories via a more personalized intervention based on individual characteristics, and ensure the containment of costs of public and private health prevention programs.
AB - Over the past three decades great efforts have been made in search of cancer chemoprevention strategies. The increase in knowledge of the long process from normal to cancer cell has enabled interventions in terms of lifestyle modifications, natural compounds or drugs to block or reverse the process. Great successes have been achieved, especially for breast and colorectal cancer. However, these strategies have yet to find clinical application on a large scale.In this article we identify the achievements, the pitfalls and the next steps to be taken to improve the efficacy and applicability of chemoprevention strategies. Among the crucial key points to be implemented are educational activities for physicians to appropriately disseminate the aim and indeed the culture of chemoprevention. It is essential to improve the risk-benefit balance, seeking the minimal active doses, intermittent schedules, a better characterization of the risk categories via a more personalized intervention based on individual characteristics, and ensure the containment of costs of public and private health prevention programs.
KW - Chemoprevention
KW - Surrogate-biomarkers
KW - Vaccines
UR - http://www.scopus.com/inward/record.url?scp=84928582571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928582571&partnerID=8YFLogxK
U2 - 10.1016/j.molonc.2014.12.006
DO - 10.1016/j.molonc.2014.12.006
M3 - Article
C2 - 25556583
AN - SCOPUS:84928582571
VL - 9
SP - 1008
EP - 1017
JO - Molecular Oncology
JF - Molecular Oncology
SN - 1574-7891
IS - 5
ER -